Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4EBP1 | Q13541 | 20/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650527 | 0.95 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650559 | 0.87 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650447 | 0.84 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650629 | 0.84 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650497 | 0.83 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650599 | 0.82 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650493 | 0.82 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650554 | 0.81 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL29650546 | 0.80 | EIF4EBP1 (1.00) | EIF4EBP1 | |
| SCHEMBL22866507 | 0.80 | EIF4EBP1 (1.00) | EIF4EBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378821-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-01 | — | — | US | disclosed |
| EP-3993875-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | EFFECTOR THERAPEUTICS, INC. (US) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378821-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | BRAF, EIF4EBP1, EIF4E | EIF4EBP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.